Search

Displaying results 1511 - 1520 of 5263 in total
  1. Drug

    Porfimer sodium

    go.drugbank.com/drugs/DB00707
    ApprovedInvestigational

    The purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentall...

  2. Drug

    CX-046684

    go.drugbank.com/drugs/DB19414
    Approved

    CX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2. It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.

  3. Drug

    Oxtriphylline

    go.drugbank.com/drugs/DB01303
    Approved

    Oxtriphylline is the choline salt form of [theophylline]. … In the US, oxtriphylline is no longer available.

  4. Drug

    Cystine

    go.drugbank.com/drugs/DB00138
    ApprovedInvestigationalNutraceuticalWithdrawn

    A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.

  5. Drug

    Calcium citrate

    go.drugbank.com/drugs/DB11093
    ApprovedInvestigational

    Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements.

    Mixtures: Calcium-magnesium With K & Zn and Vitamin D3
  6. Drug

    Lopinavir

    go.drugbank.com/drugs/DB01601
    ApprovedInvestigational

    [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself … [A191757] Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.[L12012]

  7. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. … Patients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies.

  8. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses. … [L39804] Cemiplimab was also approved by the European Commission on June 28, 2019.

  9. Drug

    Methyclothiazide

    go.drugbank.com/drugs/DB00232
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

  10. Drug

    Cantharidin

    go.drugbank.com/drugs/DB12328
    ApprovedInvestigational

    [L47496] The approval was based on positive results from 2 phase III trials, CAMP-1 and CAMP-2, where 46% and 52% of patients treated with cantharidin achieved complete molluscum clearance, respectively … [A32892] Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH™ by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients